STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world

Abstract

This large observational genomic study among patients receiving routine care highlights the negative prognostic impact of STK11m in patients with mNSCLC treated with IO or chemotherapy. These results complement previous clinical trial data and provide further evidence in the real world of a patient population that would benefit from new treatment options.

References

Page 1

	Year	Citations
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, New England Journal of Medicine	2016	9.8K
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei, L. Paz-Ares, Leora Horn, New England Journal of Medicine	2015	9.3K
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, New England Journal of Medicine	2018	6.4K
Comprehensive molecular profiling of lung adenocarcinoma Nature	2014	5.7K
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Tony Mok, Yi‐Long Wu, Iveta Kudaba, The Lancet	2019	3.2K
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, New England Journal of Medicine	2018	3.1K
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing Marcin Imieliński, Alice H. Berger, Peter S. Hammerman, Cell Tumor BiologyEngineeringTumor HeterogeneityMedicineNext-generation Sequencing	2012	1.8K
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Howard West, Michael McCleod, Maen Hussein, The Lancet Oncology MedicineMetronomic TherapyPharmacologyPathologyBronchial Neoplasm	2019	1.6K
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, Cancer Discovery	2018	1.5K
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR‐1 José M. Lizcano, Olga Göransson, Rachel Toth, The EMBO Journal	2004	1.4K

Page 1